DX126-262(DAC-001)是多禧生物公司自主研发的新一代ADC药物,由重组人源化HER2单克隆抗体 DX-CHO9 通过半胱氨酸的巯基连接 Tubulysin B 类似物形成,其中Tubulysin B 类似物是公司具有自主知识产权的高活性细胞毒素分子。目前,DX126-262正在中美两地展开对乳腺癌、胃癌的临床研究。
作者: 2019年10月9日,杭州多禧生物科技有限公司自主研发的、针对Her2阳性晚期乳腺癌和胃癌的ADC药物DX126-262(临床登记号:CTR20191224),在复旦大学附属肿瘤医院,完成I期临床试验首次乳腺癌患者用药。 DX126-262 是由重组人源化抗Her2单克隆抗体DX-CHO9 与Tubulysin B 类似物链接形成的ADC药物,是多禧生物首个进入...
HER2-targeted ADC DX126-262 combined with chemotherapy demonstrates superior antitumor efficacy in HER2-positive gastric cancer5-FluorouracilAntibody-drug conjugateCisplatincombination therapymetastasistarget therapytumorGastric cancer is a common malignant tumor with high incidence and mortality. The ...
Components: DX126-262 is an ADC drug formed by recombinant humanized anti-Her2 monoclonal antibody DX-CHO9 (IgG1) conjugated with Tub114 through a cysteine thiol linkage. Average molecular ratio of Tub114 to the antibody (ADR) in DX126-262 is about 3.5-3.8. ...
DX126-262(DAC-001)是多禧生物公司自主研发的新一代ADC药物,由重组人源化HER2单克隆抗体 DX-CHO9 通过半胱氨酸的巯基连接 Tubulysin B 类似物形成,其中Tubulysin B 类似物是公司具有自主知识产权的高活性细胞毒素分子。目前,DX126-262正在中美两地展开对乳腺癌、胃癌的临床研究。
DX126-262 is a novel HER2-targeting antibody-drug conjugate (ADC), generated by conjugating a Tubulysin B analogue to a recombinant humanized anti-HER2 monoclonal antibody through a linker containing branched hydrophilic polyethylene glycol, using thiol-maleimide chemistry to achieve drug antibody ratio...